400 results about "Racemization" patented technology

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

The invention discloses a compound as shown in a formula (I), and / or pharmaceutically acceptable salts thereof, and / or a raceme mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof, and belongs to the technical field of medicines. The invention also discloses a pharmaceutical composition containing the compound as shown in the formula (I), and the compound as shown in the formula (I) and / or a pharmaceutically acceptable salt thereof, and / or a racemic mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof, and / or the pharmaceutical composition, a pharmaceutically acceptable salt thereof, and / or a racemic mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof. The invention further discloses application of the cGAS agonist in preparation of the cGAS agonist and a medicament for treating diseases responding to activation of the cGAS-STING signal channel.

An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

The invention discloses an enzyme catalysis preparation method of a milobalin intermediate. According to the method, racemization 3-ethyl bicyclo [3.2. 0] hept-3-ene-6-ketone is used as a substrate, specific ketoreductase is used as a catalyst, (1S, 5R)-3-ethyl bicyclo [3.2. 0] hept-3-ene-6-ketone is selectively reduced into (1S, 5R)-3-ethyl bicyclo [3.2. 0] hept-3-ene-6-alcohol, and a target compound milobalin intermediate (1R, 5S)-3-ethyl bicyclo [3.2. 0] hept-3-ene-6-ketone is reserved. According to the method disclosed by the invention, only one enzyme is used, the concentration of a conversion substrate can reach 200g / L, the yield can reach 47.4%, the ee value can reach 99.8%, the operation is simple, the resolution efficiency is high, the selectivity is good, and the method can be used for industrial production.

Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, X1, X2, Y1, and Y2 are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

Provided in the present invention is a small molecule compound, which is characterized in that it is a compound or a stereoisomer, geometric isomer, tautomer, racemate, hydrate, solvate, metabolite, and pharmaceutically acceptable salt or prodrug of the compound as represented by the following structural formula: formula (I). The small molecule compound of the present invention is applicable as a highly efficient and specific JAK kinase inhibitor, specifically a Tyk2 inhibitor and / or a JAK1 inhibitor, and / or a JAK1 / Tyk2 dual inhibitor.

The invention relates to a pyrimidine derivative as well as a pharmaceutical composition and application thereof, and particularly provides a compound as shown in the following formula H, and a raceme, a stereoisomer, a tautomer, an isotope label, a solvate, a polymorphic substance, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound.

The invention belongs to the technical field of organic synthesis, and particularly relates to a preparation method and application of 3-aminopyrrolidine-1-carboxylic acid tert-butyl ester. According to the preparation method, cheap (R)-1-carboxylic acid tert-butyl ester-3-hydroxypyrrolidine is taken as a raw material, a racemic compound 5 is obtained through a two-step reaction under the action of substituted sulfonyl chloride, and racemic 3-aminopyrrolidine-1-carboxylic acid tert-butyl ester is obtained through a hydrazinolysis reaction. The preparation method provided by the invention is simple and convenient to operate, the production safety is remarkably improved, the purity and yield of the obtained target product can be further improved, and industrial production is facilitated. In addition, the invention also provides a method for preparing racemic 3-aminopyrrolidine-1-carboxylic acid tert-butyl ester by using the obtained 3-aminopyrrolidine-1-carboxylic acid tert-butyl ester.

The invention provides a method for synthesizing N-methylated polypeptide, which comprises the following steps: dissolving a carboxylic acid compound, N-methyl amino-acid ester hydrochloride or N-methyl amino-acid ester, an alkaline substance and pivaloic anhydride in an organic solvent, reacting at 15-80 DEG C for 3-10 hours, and post-treating the obtained reaction liquid to obtain an N-methyl dipeptide compound, the method comprises the following steps: removing a protecting group in an N-methyl dipeptide compound to obtain a free-state N-methyl dipeptide compound, and condensing the free-state N-methyl dipeptide compound and amino acid or N-methyl amino-acid ester protected by amino to obtain the N-methylated polypeptide, the mixed anhydride intermediate is formed in situ, and the reaction is completed in one step; according to the method, trimethylacetic anhydride is used as a condensing agent, the structure is simple, the reaction is safe, cheap and non-toxic, a large amount of nitrogen-containing byproducts are not generated in the reaction, and purification is convenient; the method is high in stereoselectivity, and racemization is avoided; according to the method, environment-friendly solvents such as ethyl acetate can be used, the reaction condition is mild, and the reaction time is short.

The invention relates to the technical field of luminescent materials, in particular to a circularly polarized phosphorescent Pt (II) complex as well as a preparation method and application thereof. The circularly polarized phosphorescent Pt (II) complex has a structure as shown in a formula (R)-I, a formula (S)-I, a formula (R)-II, a formula (S)-II, a formula (R)-III or a formula (S)-III, according to the invention, [2.2] paracyclophane is mainly used as a planar chiral skeleton, and different sites of the planar chiral skeleton are modified to obtain the circularly polarized phosphorescent Pt (II) complex which is stable in chirality and is not easy to racemize. The high-efficiency circularly polarized phosphorescent Pt (II) complex with both luminous quantum yield and circular polarization property is obtained by utilizing the advantages of a four-coordinate plane structure, high exciton utilization rate and adjustable color of the Pt (II) complex, and the high-efficiency circularly polarized phosphorescent Pt (II) complex has great research value on development of circularly polarized chiral materials. .

A specific topoisomerase inhibitor, a use as an antibody drug conjugate, and a preparation method therefor, which relate to the technical field of medicinal chemistry. The inhibitor is a compound A or a tautomer, a mesomer, a racemate, an optical antipode, a diastereoisomer, or a mixture form thereof, or a pharmaceutically acceptable salt thereof; the structure of the compound A is such that the compound may also be further prepared to obtain an antibody drug conjugate, the antibody drug conjugate has good solubility and pharmaceutical properties, and the conjugation process does not result in precipitation, the antibody drug conjugate exhibits obvious in-vivo anti-tumor activity, and shows markedly stronger anti-tumor activity when compared with a control sample.

Disclosed is a method for preparing (S)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid and derivatives thereof, comprising: taking a racemate of a compound represented by Formula (I) or a racemate of a salt of the compound represented by Formula (I) as a substrate, and making a R-isomer of the compound represented by Formula (I) in the substrate react under the catalysis of oxidative dehydrogenase to generate imino acid represented by formula (II); and converting the imino acid represented by Formula (II) into an S-isomer of the compound represented by Formula (I) in the presence of pipecolic acid reductase and a coenzyme capable of supplying hydrogen anions. The process has mild reaction conditions, strong stereoselectivity, high reaction efficiency, and high conversion rate.

The present application relates to the technical field of organic synthesis, and particularly relates to a method for preparing (+)-crispine A by means of biological enzyme resolution. First, 6,7-dimethoxy-3,4-dihydroisoquinoline-2-oxide is subjected to 1,3-dipolar cycloaddition with allyl alcohol to obtain a first compound; then the first compound is added into a sulfonylation reagent and zinc powder to obtain a racemate second compound through a three-step continuous series reaction of primary alcohol sulfonylation, nitrogen-oxygen bond cleavage and ring formation; then the second compound is mixed with vinyl acetate and biological enzyme, and chiral resolution is carried out under the action of the biological enzyme to obtain a third compound with right-handed optical rotation and a fourth compound with left-handed optical rotation; finally, the third compound is mixed with an alkaline reagent and a sulfonylation reagent, and then secondary alcohol sulfonylation is carried out to obtain a fifth compound with right-handed optical rotation; the fifth compound is mixed with a deoxidizing reagent to carry out deoxidation reaction, and (+)-crispine A is prepared. The method is simple, green and environmentally friendly, and can be produced in large quantities.

The present invention relates to an anti-tumor use of a phosphorus compound. Specifically, the present invention provides a use of a compound of formula (I), an optical isomer thereof, a racemate thereof, a solvate thereof, a pharmaceutically acceptable salt thereof or a deuterated compound thereof in preparation of a composition or a preparation, wherein the composition or the preparation is used for preventing and / or treating tumors. The compound of the present invention exhibits excellent precise therapeutic efficacy against tumors characterized by high expression of kinase B.

Provided herein are methods composition for treating lung cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate, or enantiomer thereof, wherein Formula I is a gold complex having a structure Au(L)(L′)n, wherein: n is an integer from 1 to 3; L is an imidazolyl-based N-heterocyclic carbene (NHC) ligand; and each L′ is independently selected from an imidazolyl-based NHC ligand, a triaryl phosphine, or a halide.

The invention discloses a fused ring compound, a pharmaceutical composition containing the fused ring compound and application. The compound has a structure as shown in a formula (I) or a tautomer, a meso-mer, a raceme, an enantiomer, a diastereoisomer or a mixture form, a metabolite, a metabolism precursor, an isotope substitution form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorphic substance or an eutectic substance thereof, the compound can be used for treating one or more cancers caused by KRAS mutation.

The invention discloses a method for preparing an ester compound and a macrolide compound, and belongs to the technical field of organic chemistry, the preparation method of the ester compound is as follows: in an organic solvent, an alpha-carbonyl alkenyl ester compound reacts with alcohol or phenol under the catalytic condition of alkali to obtain the ester compound; the preparation method of the macrolide compound comprises the following step: in an organic solvent, carrying out intramolecular hydroxyl reaction on an alpha-carbonyl alkenyl ester compound under the catalysis condition of alkali or acid, thereby obtaining the macrolide compound. The method is wide in substrate range, high in practicability and high in yield, racemization of a carboxylic acid alpha-chiral center can be inhibited in intermolecular esterification reaction and macrocyclic lactonization reaction, and the method can be applied to total synthesis of a Brevicidine natural product containing a 13-membered cyclic ester peptide core structure; the method disclosed by the invention has the advantages of mild reaction conditions, simplicity, easiness in operation, wide substrate adaptability, no racemization of the product and the like.

The invention provides a synthesis method of a chiral non-racemic C2 symmetric bidentate bis (oxazoline) aryl alkenyl compound. The chiral non-racemic C2 symmetric bidentate bisoxazoline aryl alkenyl compound is synthesized from an aldehyde compound and non-racemic C2 symmetric bidentate bisoxazoline with active methylene through a dehydration condensation reaction, and the method is simple and efficient; and the blank of realizing the chiral non-racemic C2 symmetric bidentate bisoxazoline aryl alkenyl compound through the condensation reaction is filled, so that the chiral non-racemic C2 symmetric bidentate bisoxazoline aryl alkenyl compound has important significance in large-scale application of the compound as a ligand in transition metal catalytic reaction.

The invention discloses a fused ring compound, a pharmaceutical composition containing the fused ring compound and application. The compound has a structure as shown in a formula (I) or a tautomer, a meso-mer, a raceme, an enantiomer, a diastereoisomer or a mixture form, a metabolite, a metabolism precursor, an isotope substitution form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorphic substance or an eutectic substance thereof. The compound can be used for treating cancers caused by KRAS mutation, the cancers caused by KRAS mutation are selected from one or more of cancers caused by KRASG12C, KRASG12V, KRASG12A and G12D mutation, and particularly, the compound can be used as a G12D inhibitor and has relatively high inhibitory activity.

The invention discloses a method for directly preparing a racemic oxidation product from a fennerenone enantiomer through photocatalysis, and belongs to the technical field of organic synthesis.The method comprises the steps that an R-type fennerenone isomer is taken to be placed in a reaction bottle, a photosensitizer containing iridium or ruthenium is added, and a solvent is added at the speed of 0.1 M in the air atmosphere; the method comprises the following steps: dissolving 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2, 8-dimethyl-1, 6-naphthyridine-3-formamide in a solvent, stirring, transferring a mixture into a photoreactor of a blue light LED (Light Emitting Diode) with the wavelength of 455-465 nm, stirring, transferring a mixed solution after the reaction is finished into a round-bottom flask, purifying a volatile solvent to obtain a product 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2, 8-dimethyl-1, 6-naphthyridine-3-formamide, and carrying out chiral HPLC (High Performance Liquid Chromatography) analysis on the product. High temperature, high pressure or a strong oxidant is not needed, and reaction conditions are mild; oxygen in air is oxidized at room temperature, so that energy consumption and pollutant generation are reduced; compared with the traditional oxidation condition, the method does not need to undergo the process of oxidation first and then high-temperature induced racemization, and the racemization product can be directly obtained.

A sulfonamide compound and a pharmaceutical use thereof, specifically relating to a compound of general formula (II) or a racemate, stereoisomer, tautomer, pharmaceutically acceptable salt, and intermediate thereof, a preparation method therefor, and a use thereof in the preparation of drugs for treating solid tumors.

The invention discloses a pyridazinone compound as well as a pharmaceutical composition and application thereof. The structure of the compound is shown as a formula (I), and the compound comprises a racemate, a stereoisomer, a tautomer, a nitrogen oxide, a stable isotope compound, a metabolite, a solvate, a pharmaceutically acceptable salt or a mixture of the racemate, the stereoisomer, the tautomer, the nitrogen oxide, the stable isotope compound and the metabolite. The compound has a proper half-life period, can be decomposed in blood through injection or oral administration to generate a PARP7 inhibitor compound and dextroborneol, and the PARP7 inhibitor compound and dextroborneol can penetrate through a blood brain barrier, show a good synergistic interaction effect, are beneficial to medicine formation and have a clinical application prospect in prevention or / and treatment of cerebral apoplexy.

The present invention relates to a process for the preparation of (±)‑2‑exo‑(2‑methylbenzyloxy)‑1‑methyl‑4‑isopropyl‑7‑oxabicyclo[2.2.1]heptane of formula (I), any of its individual enantiomers or any non-racemic mixture thereof, comprising the steps of: (a) reacting (±)‑2‑exo‑hydroxy‑1‑methyl‑4‑isopropyl‑7‑oxabicyclo[2.2.1]heptane of formula (II), any of its individual enantiomers or any non-racemic mixture thereof, with a 2-methylbenzyl compound of formula (III), wherein X is a leaving group, in the presence of at least one base capable of forming water or a C1-C4 alkyl alcohol under the reaction conditions and at least one inert organic solvent, and (b) simultaneously removing water, C1-C4 alkyl alcohol or any mixture thereof from the reaction mixture.

The invention belongs to the field of preparation of polypeptide drugs, and discloses a synthesis method of tilpotide, which mainly comprises the following steps: 1) taking amino resin as initial resin, and coupling with protected amino acid and polypeptide fragments by adopting a solid-phase synthesis method to obtain peptide resin of tilpotide; wherein the Glu3-Gly4 adopts a Glu-Gly dipeptide fragment, the Thr5-Phe6 adopts a Thr-Phe dipeptide fragment, the Lys20 adopts a Lys [AEA-AEA-gamma-Glu-C20] fragment, and the Gly29-Gly30 adopts a Gly-Gly dipeptide fragment; 2) cracking the peptide resin to obtain crude peptide of the tilpotide; and (3) purifying the crude peptide by reversed-phase chromatography to obtain the fine peptide of the tilpotide. The invention provides a synthesis method of telpotide, which can effectively reduce the generation of [D-Glu] racemization impurities, [D-Thr] racemization impurities, [D-Phe] racemization impurities and [+ Gly] impurities, thereby enhancing the purity and yield of the telpotide, obviously lowering the difficulty of purifying crude peptide, greatly enhancing the total yield of the telpotide on the premise of ensuring the purity of the telpotide, and lowering the production cost of the telpotide. In addition, synthesis of a plurality of fragments can be performed simultaneously, so that the synthesis time is shortened. The purity of the crude tirpotide prepared by the method can reach 86.22% or above, and the yield of the crude tirpotide is 101.51% or above. Through simple purification steps, the impurities in the tilpotide are basically removed, the purity of refined peptide can reach 99.21% or above, the maximum single impurity is lower than 0.15%, the total yield can reach 63.02% or above, the synthesis cost is reduced, and industrial mass production is facilitated.

The present application provides a compound having a structure shown in Formula I, II or III or its enantiomer, diastereoisomer, racemate, stereoisomer, geometric isomer, nitroxide, metabolite or its pharmaceutically acceptable salt, ester, solvate, hydrate, isotopically labeled compound or prodrug. The non-fenofibrate 4-position ether derivative of the present application has an excellent xanthine oxidase activity inhibitory activity.

The invention relates to processes for preparing carbaprostacyclin analogues and intermediates prepared from the processes. The invention also relates to cyclopentenone intermediates in racemic or optically active form.

The invention discloses a chiral phenol calix [4] aryl porous organic molecular cage material as well as a preparation method and application thereof. A chiral calix [4] arene raceme and an acyl chloride chiral auxiliary agent are used as initial raw materials to react to prepare a pair of diastereoisomers, gram-grade separation is achieved through silica gel column chromatography, then the chiral auxiliary agent is removed respectively, and the single enantiomer chiral phenol calix [4] arene compound with the ee value being 99.9% or above can be obtained. The preparation method comprises the following steps of: synthesizing tetraaldehyde chiral phenol calix [4] arene by introducing an aldehyde group unit on the tetraaldehyde chiral phenol calix [4] arene through Duff reaction, and assembling the tetraaldehyde chiral phenol calix [4] arene serving as a construction element with a polyamino organic synthesizer to prepare the chiral phenol calix [4] arene porous organic cage with a larger cavity. The preparation method of the chiral porous organic cage does not need a catalyst, the preparation process is simple, operation is easy and convenient, expansibility is good, the yield is high, and the prepared chiral molecular cage is large in cavity, large in specific surface area and good in repeatability and can be used for chiral recognition and gas adsorption.

The present invention relates to an integrin ligand key intermediate and a preparation method therefor, and specifically provides a new process for synthesizing target compound (7). Compared with existing synthesis processes, the new synthesis process can avoid racemic intermediate compound resolution, improve yields and reduce costs, thereby strongly supporting cost reduction and large-scale production of an αvβ6 integrin ligand.

This invention relates to the application of cyclic quaternary ammonium bases in the preparation of racemic nicotine. The structure of the cyclic quaternary ammonium base is shown in Formula I or Formula II, where n is an integer from 1 to 7; t and m are independently integers from 1 to 4. When the cyclic quaternary ammonium base of this invention is used as a catalyst in the preparation of racemic nicotine, racemic nicotine can be synthesized in one step. This method uses S-nicotine as a raw material and has the advantages of readily available raw materials, fewer reaction steps, fewer reaction byproducts, less likelihood of introducing other impurities, no introduction of other carbon sources during preparation, and ease of large-scale preparation.